Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLZMU2)

Drug Name

Asundexian Drug Info

Synonyms

Asundexian; Asundexian [INN]; 2064121-65-7; LA585UM8DE; UNII-LA585UM8DE; 4-[[(2S)-2-[4-[5-chloro-2-[4-(trifluoromethyl)triazol-1-yl]phenyl]-5-methoxy-2-oxopyridin-1-yl]butanoyl]amino]-2-fluorobenzamide; 1(2H)-Pyridineacetamide, N-(4-(aminocarbonyl)-3-fluorophenyl)-4-(5-chloro-2-(4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl)phenyl)-alpha-ethyl-5-methoxy-2-oxo-, (alphaS)-; 4-[[(2~{S})-2-[4-[5-chloranyl-2-[4-(trifluoromethyl)-1,2,3-triazol-1-yl]phenyl]-5-methoxy-2-oxidanylidene-pyridin-1-yl]butanoyl]amino]-2-fluoranyl-benzamide; Asundexian [WHO-DD]; SCHEMBL20360602; GTPL11710; XYWIPYBIIRTJMM-IBGZPJMESA-N; BDBM413842; GLXC-25353; EX-A6019; US10421742, Example 235; AKOS040757232; BAY2433334; BAY 2433334; BAY-2433334; MS-30546; example 235 [WO2017005725A1]; HY-137431; CS-0138630; 1(2H)-PYRIDINEACETAMIDE, N-(4-(AMINOCARBONYL)-3-FLUOROPHENYL)-4-(5-CHLORO-2-(4-(TRIFLUOROMETHYL)-1H-1,2,3-TRIAZOL-1-YL)PHENYL)-.ALPHA.-ETHYL-5-METHOXY-2-OXO-, (.ALPHA.S)-; 4-({(2S)-2-[4-{5-Chloro-2-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)-2-fluorobenzamide (Enantiomer 2); 4-[(2S)-2-(4-{5-chloro-2-[4-(trifluoromethyl)-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1-yl)butanamido]-2-fluorobenzamide; QV3

Indication

Disease Entry	ICD 11	Status	REF
Ischemic stroke	8B11.5Z	Phase 3	[1]

Cross-matching ID

PubChem CID: 135206011
TTD Drug ID: DMLZMU2

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Coagulation factor XI (F11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
A186	DMHJ0EB	Clotting disorder	3B4Z	IND submitted	[3]
Abelacimab	DM09YTN	Atrial fibrillation	BC81.3	Phase 2	[4]
MK-2060	DM79A32	Thrombosis	DB61-GB90	Phase 2	[5]
EP-7041	DMV0MHI	Thrombosis	DB61-GB90	Phase 1	[6]
AB023	DMBG9HI	End-stage renal disease	GB61.5	Phase 1	[7]
A336	DMVQG8G	Clotting disorder	3B4Z	Phase 1	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Coagulation factor XI (F11)	TTJCPUT	FA11_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05686070) A Multicenter, International, Randomized, Placebo Controlled, Double-blind, Parallel Group and Event Driven Phase 3 Study of the Oral FXIa Inhibitor Asundexian (BAY 2433334) for the Prevention of Ischemic Stroke in Male and Female Participants Aged 18 Years and Older After an Acute Non-cardioembolic Ischemic Stroke or High-risk TIA. U.S.National Institutes of Health.
2	Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa. J Thromb Haemost. 2022 Jun;20(6):1400-1411.
3	Clinical pipeline report, company report or official report of Klus Pharma
4	Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa. J Thromb Haemost. 2022 Feb;20(2):307-315.
5	Clinical pipeline report, company report or official report of MSD
6	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7	Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial. Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):799-809.